Abstract
BackgroundVitiligo is a common dermatological disorder of chronic depigmentation which is phenotypically characterized by white macules on the skin caused as a result of the systematic destruction of functional melanocytes. This review provides an overview of vitiligo, its etiopathogenesis and disease management, and also discusses the scope of network-interaction studies and polypharmacological studies in understanding vitiligo disease module.MethodsA narrative review of the relevant published literatures known to the authors that comprehensively discussed about vitiligo and its implications was conducted.ResultsEmerging evidence underlines the existing connection between deregulated miRNA function and vitiligo pathogenesis. It has also been linked with autoimmunity for the cause of melanocyte death in susceptible individuals. Alteration of genetic factors involved in immune responses and melanogenesis along with environmental factors are central to disease manifestation. Screening methods as such are not available for vitiligo, and the diagnosis is based on the assessment of the absence of melanocytes from the lesions in the affected area. With the occurrence of vitiligo at any age, most people typically develop it at a young age. Depending on the disease course and duration, clinical management primarily involves disease stabilization either by repigmentation or depigmentation of the skin.ConclusionsSeveral questions remain unsolved which indeed makes vitiligo an excellent model for studying autoimmune and degenerative processes. An understanding of the underlying degenerative mechanisms and unraveling the biological mediators of melanocyte loss will open up avenues for testing novel therapeutic approaches in vitiligo management. Such studies can revolutionize our apprehension of the molecular interconnections that underpin vitiligo pathogenesis.
Highlights
ResultsEmerging evidence underlines the existing connection between deregulated miRNA function and vitiligo pathogenesis
Vitiligo is a common dermatological disorder of chronic depigmentation which is phenotypically characterized by white macules on the skin caused as a result of the systematic destruction of functional melanocytes
Experimental, and clinical studies have unraveled significant pathways in vitiligo pathogenesis that have helped in identifying targets for the development of efficient treatment approaches for disease management
Summary
Emerging evidence underlines the existing connection between deregulated miRNA function and vitiligo pathogenesis. It has been linked with autoimmunity for the cause of melanocyte death in susceptible individuals. Alteration of genetic factors involved in immune responses and melanogenesis along with environmental factors are central to disease manifestation. Screening methods as such are not available for vitiligo, and the diagnosis is based on the assessment of the absence of melanocytes from the lesions in the affected area. With the occurrence of vitiligo at any age, most people typically develop it at a young age. Depending on the disease course and duration, clinical management primarily involves disease stabilization either by repigmentation or depigmentation of the skin
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.